Sodium Bicarbonate for Health & Longevity - Quick Reference Sheet

Sodium Bicarbonate for Health & Longevity

Created on 09/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Sodium bicarbonate is baking soda, an inexpensive salt that neutralizes stomach acid and adds to the body's acid-neutralizing reserve, used for heartburn, high-intensity exercise, and kidney disease. Benefit for high-intensity interval training is best established. Kidney benefit remains contested and evidence for healthy aging uncertain. Main risks are digestive distress at high doses, a meaningful sodium load, and rare serious events from overly alkaline blood or stomach rupture. (Full Review)

Protocol

Ergogenic protocol
0.2–0.3 g/kg, 60–180 min before exercise
Single dose; or 0.4–0.5 g/kg daily split over 3–7 days
Healthy-aging protocol
¼–½ teaspoon (about 1.2–2.3 g) in water, once or twice daily
Split doses with meals; trials in older adults used 67.5 mmol/day (about 5.7 g)
Kidney-disease protocol
0.5–1.0 mEq/kg daily (about 3–6 g for 70 kg)
Nephrologist-prescribed; targets serum bicarbonate 22–26 mmol/L
Time to effect
Exercise performance
60–180 minutes
After dosing; blood bicarbonate peaks 60–90 min (solution) or 120–180 min (capsules)
Kidney function
1–2 years
Effects in chronic kidney disease emerge only over this span
Serum bicarbonate
2–4 weeks
Blood bicarbonate corrects within this window

Benefits

Contraindications
  • Heart failure (NYHA class III–IV, or any recent acute worsening)
  • Advanced chronic kidney disease (eGFR below 30 mL/min/1.73 m²) or dialysis, unless prescribed and supervised by a nephrologist
  • Uncontrolled hypertension (≥160/100 mm Hg)
  • Sodium restriction below 2,000 mg/day for medical reasons
  • Cirrhosis with ascites or edema
  • Existing metabolic alkalosis (serum bicarbonate above 30 mmol/L), hypokalemia (potassium below 3.5 mmol/L), or low calcium
  • Pregnancy, unless directed by a physician
  • Binge-eating disorder or bulimia
  • Severe abdominal pain or suspected appendicitis
  • Children under 5 years
Key Interactions
  • Acid-dependent prescription drugs (ketoconazole, itraconazole, atazanavir, dasatinib, iron salts)
  • Drugs cleared faster in alkaline urine (salicylates such as aspirin, lithium, methotrexate)
  • Drugs retained in alkaline urine (amphetamine stimulants, pseudoephedrine, quinidine, memantine, flecainide)
  • Diuretics (fluid-removing drugs) and corticosteroids (steroid anti-inflammatories) (hydrochlorothiazide, furosemide, prednisone)
  • Enteric-coated tablets (enteric-coated aspirin, bisacodyl, delayed-release omeprazole)
  • OTC effervescent antacids (Alka-Seltzer, calcium carbonate antacids)
  • Calcium supplements and large dairy intake (calcium carbonate, calcium citrate)
  • Additive alkalinizing supplements (potassium citrate, magnesium citrate, sodium citrate)
  • Additive sodium sources (electrolyte drinks, salt tablets)
  • Performance supplements (beta-alanine, creatine, caffeine)
  • Sodium-restricted diets

Risk & Side Effects

  • High: Gastrointestinal distress
  • Medium: More adverse events and lower quality of life in older adults with advanced kidney disease
  • Low: Higher blood pressure and fluid retention; metabolic alkalosis and electrolyte disturbances; spontaneous gastric rupture; calcium-alkali syndrome
  • Speculative: Vascular calcification; acid rebound and masked digestive disease

Monitoring

Marker Target Why
Serum bicarbonate (total CO₂) 24–26 mmol/L Confirms acid deficit and response
Serum potassium 4.0–4.8 mmol/L Detects alkalosis-driven potassium loss
Serum sodium 138–142 mmol/L Detects sodium excess
Serum chloride 100–106 mmol/L Flags alkalosis pattern
Creatinine with eGFR eGFR ≥90 mL/min/1.73 m² or stable Tracks kidney function
Urine albumin-to-creatinine ratio <10 mg/g Early kidney damage marker
Serum calcium 9.2–10.0 mg/dL Screens for calcium-alkali syndrome
Blood pressure <120/80 mm Hg Detects sodium-driven rise
First-morning urine pH 6.5–7.0 Confirms alkali effect; guards against over-alkalinization
Body weight No established target; track change from own baseline Early sign of fluid retention

Cadence: Baseline panel before regular use; serum bicarbonate, potassium, and sodium at 2–4 weeks, then every 3 months during the first year, then every 6–12 months; creatinine with eGFR and urine albumin every 6–12 months; home blood pressure and weight weekly during the first month, then monthly.

Qualitative Assessment

  • Digestive tolerance (bloating, belching, stool changes)
  • Ankle or leg swelling
  • Energy and exercise tolerance during hard intervals
  • Muscle cramps, twitching, or tingling (possible alkalosis)
  • Breathlessness when lying flat (possible fluid overload)
  • Heartburn frequency, if used as an antacid